These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16224383)

  • 1. New approaches to the treatment of thrombocytosis.
    Fruchtman S
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):92-3. PubMed ID: 16224383
    [No Abstract]   [Full Text] [Related]  

  • 2. [The use of anagrelide to treat thrombocytosis in connection with the chronic myeloproliferative disease].
    Jantunen E; Penttilä K; Kuittinen T; Nousiainen T
    Duodecim; 2006; 122(4):453-7. PubMed ID: 16623100
    [No Abstract]   [Full Text] [Related]  

  • 3. Anagrelide: 20 years later.
    Emadi A; Spivak JL
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy.
    D'adda M; Micheletti M; Drera M; Ferrari S; Rossi G
    Leuk Lymphoma; 2008 Nov; 49(11):2216-8. PubMed ID: 19021067
    [No Abstract]   [Full Text] [Related]  

  • 5. Essential thrombocytosis: diagnostic and treatment dilemmas.
    Dugan V; Higginbotham R; Gilbert J; Lipscomb G; Lopez FA
    J La State Med Soc; 2003; 155(6):306-13. PubMed ID: 14750750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
    Gilbert HS
    Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [What should follow a treatment for pruritus in thrombocytosis?].
    Wollina U
    Dtsch Med Wochenschr; 2003 Mar; 128(12):631. PubMed ID: 12649803
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombocytosis.
    Cheung MC; Hicks LK; Pendergrast J
    N Engl J Med; 2004 Jun; 350(24):2524-5; author reply 2524-5. PubMed ID: 15190151
    [No Abstract]   [Full Text] [Related]  

  • 9. Thrombocytosis--report of a case.
    Thomas M; Pavithran K; Salil ; Somarajan A
    J Assoc Physicians India; 2000 Apr; 48(4):441-2. PubMed ID: 11273186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R; Adam H; Widmer L; Honegger HP
    Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombocytosis.
    Schafer AI
    N Engl J Med; 2004 Mar; 350(12):1211-9. PubMed ID: 15028825
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary thrombocythemia: a current perspective.
    Mughal TI
    Stem Cells; 1995 Jul; 13(4):355-9. PubMed ID: 7549894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anagrelide--a new drug to reduce platelets in myeloproliferative diseases].
    Bennett M
    Harefuah; 1999 May; 136(9):717-20. PubMed ID: 10955097
    [No Abstract]   [Full Text] [Related]  

  • 14. Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient.
    Jensen AW; Tefferi A; Arndt CA
    J Pediatr Hematol Oncol; 2007 Mar; 29(3):156-9. PubMed ID: 17356393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary thrombocytosis and myocardial ischemic syndrome in a young woman.
    Adlakha A; Bechard DL; Geer MR
    Am Heart J; 1992 Mar; 123(3):786-90. PubMed ID: 1539533
    [No Abstract]   [Full Text] [Related]  

  • 16. Modifying the Effects of Cytoreductive Drugs on Kidney Function in Myeloproliferative Neoplasms.
    Krečak I; Lucijanić M
    Pharmacology; 2021; 106(7-8):451-452. PubMed ID: 34139702
    [No Abstract]   [Full Text] [Related]  

  • 17. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
    Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review.
    Hong Y; Erusalimsky JD
    Platelets; 2002 Nov; 13(7):381-6. PubMed ID: 12487784
    [No Abstract]   [Full Text] [Related]  

  • 20. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
    N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.